Loading... Please wait... Loading... Please wait...
ESTIMATED
04/25/2024
04/25/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 5 | -$1.49 | -$1.49 | -$1.49 |
| Q2 2024 | 16 | $1.43 | $1.70 | $1.59 |
| Q3 2024 | 7 | $1.74 | $1.74 | $1.74 |
| Q4 2024 | 13 | $1.77 | $1.77 | $1.77 |
| Q1 2025 | 10 | $1.65 | $1.65 | $1.65 |
| Q2 2025 | 8 | $1.73 | $1.73 | $1.73 |
| Q3 2025 | 8 | $1.84 | $1.84 | $1.84 |
| Q4 2025 | 14 | $2.02 | $2.02 | $2.02 |
Gilead Sciences, Inc. last posted its earnings results on Thursday, April 25th, 2024. The company reported $-1.32 earnings per share for the quarter, topping analysts' consensus estimates of $-1.49 by $0.17. The company had revenue of 6.69 B for the quarter and had revenue of 27.12 B for the year. Gilead Sciences, Inc. has generated $5 earnings per share over the last year ($4.5 diluted earnings per share) and currently has a price-to-earnings ratio of 176.77. Gilead Sciences, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/08/2024 | Q1 2024 | -$3.34 | $6.36 B | $6.69 B | 02/23/2024 | Q4 2023 | $1.15 | $7.10 B | $7.12 B | 11/07/2023 | Q3 2023 | $1.91 | $1.75 | -0.16 | $7.05 B | 08/04/2023 | Q2 2023 | $0.84 | $6.60 B | 05/03/2023 | Q1 2023 | $0.81 | $6.33 B | $6.35 B | 02/22/2023 | Q4 2022 | $1.31 | $6.64 B | $7.39 B | 11/02/2022 | Q3 2022 | $1.43 | $7.04 B | 08/08/2022 | Q2 2022 | $0.91 | $6.26 B | 05/04/2022 | Q1 2022 | $0.01 | $6.59 B | 02/23/2022 | Q4 2021 | $0.30 | $6.61 B | $7.24 B | 11/03/2021 | Q3 2021 | $2.06 | $6.29 B | $7.42 B | 08/05/2021 | Q2 2021 | $1.21 | $6.08 B | $6.22 B | 05/06/2021 | Q1 2021 | $1.38 | $6.42 B | 02/25/2021 | Q4 2020 | $1.24 | $7.08 B | $7.42 B | 11/03/2020 | Q3 2020 | $0.29 | $6.29 B | $6.58 B | 08/06/2020 | Q2 2020 | -$2.66 | $5.29 B | $5.14 B | 05/05/2020 | Q1 2020 | $1.23 | $5.55 B | 02/24/2020 | Q4 2019 | $2.13 | $5.72 B | $5.88 B | 11/05/2019 | Q3 2019 | -$0.92 | $5.61 B | $5.60 B | 08/06/2019 | Q2 2019 | $1.48 | $5.53 B | $5.69 B |
|---|
A. Gilead Sciences, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 8th, 2024 based off last year's report dates.
A. In the previous quarter, Gilead Sciences, Inc. (NASDAQ:GILD) reported $-1.32 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.49 by $0.17.
A. The conference call for Gilead Sciences, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Gilead Sciences, Inc.'s latest earnings report can be read online.
A. Gilead Sciences, Inc. (NASDAQ:GILD) has a recorded annual revenue of $27.12 B.
A. Gilead Sciences, Inc. (NASDAQ:GILD) has a recorded net income of $27.12 B. Gilead Sciences, Inc. has generated $4.54 earnings per share over the last four quarters.
A. Gilead Sciences, Inc. (NASDAQ:GILD) has a price-to-earnings ratio of 176.77 and price/earnings-to-growth ratio is 7.35.
